Clinical Study on the Application of Yashiro and RH Catheter for Transcatheter Arterial Chemoembolization
International Journal of Clinical Oncology and Cancer Research
Volume 1, Issue 1, December 2016, Pages: 26-29
Received: Dec. 5, 2016; Accepted: Dec. 21, 2016; Published: Jan. 10, 2017
Views 3039      Downloads 101
Authors
Choe Won-Gyom, Pyongyang Medical College, Kim Il Sung University, Pyongyang, Democratic People’s Republic of Korea
Song U-Il, Pyongyang Medical College, Kim Il Sung University, Pyongyang, Democratic People’s Republic of Korea
Article Tools
Follow on us
Abstract
We analyze the impact on the post-operative syndrome of application of Yashiro and RH catheters to TACE. We analyze the superselective success rate of Yashiro and RH catheters in terms of hours and epiphenomenon and the impact on the post-operative syndrome of application of both of these catheters using blood test, objective indices. The superselection was successful 45 times using Yashiro catheter and the success rate was 93.75%, and 41 times using RH catheter, and the success rate 78.84%. The average time until the superselection was 347.39±29.44(s) in Yashiro catheter and 652.97±203.36(s) in RH catheter. And there were 6 cases (16.6%) of the prolongation of the operating time due to vascular spasm in RH catheter group. In Yashiro catheter group the moderate increase of transaminase and ESR was observed 7 days after operation, then it returned to the baseline on 14th day. But in RH catheter group the severe increase of these indices was observed 7 days after operation, and then it has been decreasing gradually on 14th day.(p<0.05). Our study suggests that TACE using Yashiro catheter is relatively safe approach in terms of postoperative syndrome, because it increases success rate of superselection and reduces the overall operating time.
Keywords
Hepatocellular Carcinoma (HCC), Transcatheter Arterial Chemoembolization (TACE), Yashiro Catheter, RH Catheter
To cite this article
Choe Won-Gyom, Song U-Il, Clinical Study on the Application of Yashiro and RH Catheter for Transcatheter Arterial Chemoembolization, International Journal of Clinical Oncology and Cancer Research. Vol. 1, No. 1, 2016, pp. 26-29. doi: 10.11648/j.ijcocr.20160101.14
Copyright
Copyright © 2016 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
D. M. Parkin, F. Bray, J. Ferlay, and P. Pisani, “Global cancer statistics, 2002,” Ca-A Cancer Journal for Clinicians, vol. 55, no.2, pp. 74–108, 2005.
[2]
J. M. Llovet, A. Burroughs, and J. Bruix, “Hepatocellular carcinoma,” Lancet, vol. 362, no. 9399, pp. 1907–1917, 2003.
[3]
J. M. Llovet, C. Br´u, and J. Bruix, “Prognosis of hepatocellular carcinoma: the BCLC staging classification,” Seminars in Liver Disease, vol. 19, no. 3, pp. 329–337, 1999.
[4]
J. M. Llovet, M. I. Real, X. Monta˜na et al., “Arterial embolization or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial,” Lancet, vol. 359, no. 9319, pp. 1734–1739, 2002.
[5]
C. M. Lo, H. Ngan, W. K. Tsoet al., “Randomizedcontrolledtrial of transarterial Lipiodol chemoembolization for unresectable hepatocellular carcinoma,” Hepatology, vol. 35, no. 5, pp. 1164–1171, 2002.
[6]
C. Camm`a, F. Schepis, A. Orlando et al., “Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials,” Radiology, vol.224, no. 1, pp. 47–54, 2002.
[7]
D. Doyon, A. Mouzon, A. M. Jourde et al., “Hepatic, arterial embolization in patients with malignant liver tumors,” Annales de Radiologie, vol. 17, pp. 593–603, 1974.
[8]
H. Nakamura, T. Hashimoto, H. Oi et al., “Treatment of hepatocellular carcinoma by segmental hepatic artery injection of adriamycin-in-oil emulsion with overflow to segmental portal veins,” Acta Radiologica, vol. 31, no. 4, pp. 347–349, 1990.
[9]
H. Nakamura, T. Hashimoto, H. Oi, and S. Sawada, “Transcatheter oily chemoembolization of hepatocellular carcinoma,” Radiology, vol. 170, no. 3, pp. 783–786, 1989.
[10]
M. Yoshikawa, H. Saisho, M. Ebara et al., “A randomized trial of intrahepatic arterial infusion of 4′-epidoxorubicin with Lipiodol versus 4′-epidoxorubicin alone in the treatment of hepatocellular carcinoma” Cancer Chemotherapy and Pharmacology, vol. 33, pp. S149–S152, 1994.
[11]
C. J. Yoon, J. W. Chung, J. H. Park et al., “Transcatheter arterial chemoembolization with paclitaxel-lipiodol solution in rabbit VX2 liver tumor,” Radiology, vol. 229, no. 1, pp. 126–131, 2003.
[12]
K. Takayasu, Y. Shima, Y. Muramatsu et al., “Hepatocellular carcinoma: treatment with intraarterial iodized oil with and without chemotherapeutic agents,” Radiology, vol. 163, no. 2, pp. 345–351, 1987.
[13]
Satoru Murata, Takahiko Mine et al., Transcatheter Arterial Chemoembolization Based on Hepatic Hemodynamics for Hepatocellular Carcinoma The ScientificWorld Journal Volume 2013, Article ID 479805, 8 pages
[14]
Geschwind JFH. Chemoembolization for hepatocellular carcinoma: where does the truth lie? J Vasc Interv Radiol 2002; 13:991–994.,
[15]
Liu Rong, Wang Jianhua, Zhou Kangrong, etc. “Comparative Study of Magnetic Resonance Imaging and Pathology in Patients after primary hepatocellular carcinoma chemoembolization”, Chinese Journal of Hepatology, 2005, 10: 754-758.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186